Switching from beta-blockers to digoxin as first line therapy for older patients with AF could produce £100m in NHS savings annually.

The following is a summary of “Cost-effectiveness of digoxin versus beta blockers in permanent atrial fibrillation: the Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) ...

To date, there is insufficient evidence to support the use of any upstream therapy after AF catheter ablation. ACE-I: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker ...

ACE-I: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; AF: Atrial fibrillation; CFAE: Complex-fractionated atrial electrogram ablation; CVI: Cavotricuspid isthmus ...

A study from the University of Birmingham, UK, has indicated that the use of digoxin could lead to substantial cost savings ...

The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating older patients with atrial fibrillation and heart failure.

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating ...

The RATE-AF trial included 160 patients and randomly assigned them to receive digoxin or beta-blockers for 12 months. An economic analysis was conducted to work out cost-effectiveness. Among the ...